HSPC-sparing treatments for RB-positive abnormal cellular proliferation

摘要

This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.

主权项

1. A method for the treatment of cancer in a host, wherein the cancer is Retinoblastoma-positive (Rb) and selected from the group consisting of breast cancer, colon cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, and glioblastoma, comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.